BeiGene Reports Results from a Comparative Analysis of Brukinsa vs Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Shots:
- The company evaluated the efficacy of Brukinsa vs acalabrutinib in a Matching Adjusted Indirect Comparison (MAIC) based on the results from the P-III (ALPINE) & (ASCEND) clinical trials among patients (n=327 & 155) with r/r CLL
- The study depicted significant PFS, CR & OS results in patients receiving Brukinsa vs acalabrutinib which. Earlier, findings from another MAIC analysis depicted similar efficacy data & different safety data with Brukinsa vs acalabrutinib in r/r CLL patients
- The company expects to present the data from the MAIC analysis at AICHM 2024. Brukinsa is a BTK inhibitor that has shown the potential to inhibit the proliferation of malignant B cells
Ref: BeiGene | Image: BeiGene
Related News:- BeiGene’s Brukinsa with Obinutuzumab Receives the EC’s Approval for the Treatment of Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
